News

KSHB talked to Dr. Dany Jacob about new diagnostic testing that's giving patients suffering from unexplained chest pain answers.

During Heart Month, we talk about why prevention is key and exciting new research that reveals there may be a new way to help slow aging and lengthen our lifespan.

During Heart Month, we are talking about the risks of undiagnosed heart failure and treatment options for those with heart failure.

TCTMD talked to Dr. Vittal Hejjaji about a large registry study that looked at when patients quit smoking following an atherosclerotic cardiovascular disease event.

During Heart Month, we are talking about atrial fibrillation, the recent changes in guidelines, and how Saint Luke’s is leading the way in innovative treatments for those who have a-fib.

Saint Luke’s Mid America Heart Institute was the first in Kansas and Missouri, and one of only 27 US institutions, to participate in PULSED AF clinical trial.

The groundbreaking STEP-HFpEF study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named one of the top advances by the American Heart Association.

TAVR in asymptomatic and minimally symptomatic patients is associated with a high survival rate, but relatively minor improvements, according to new research.

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.